Supplemental Table 1 Keywords

PUBMED

(PRP OR "platelet-rich" OR "platelet rich") AND (anastom* OR colorectal OR colon* OR

intestinal OR intestine OR bowel OR abdom* OR peritoneal OR intraperitoneal)

EMBASE

(PRP OR "platelet-rich" OR "platelet rich") AND (anastom* OR colorectal OR colon* OR

intestinal OR intestine OR bowel OR abdom* OR peritoneal OR intraperitoneal)

SCOPUS

(PRP OR "platelet-rich" OR "platelet rich") AND (anastom* OR colorectal OR colon* OR

intestinal OR intestine OR bowel OR abdom* OR peritoneal OR intraperitoneal)

| Author (year) | Allocation sequence generation and application: adequate? | Similar Baseline characteristics between groups? | Allocation concealment: Adequate? | Random housing? | Blinded caregivers/investigators? | Random outcome assessment? | Blinded outcome assessors? | Incomplete outcome data: Adequately addressed? | Was the study free of selective outcome reporting? | Was the study free of other sources of bias? |
|--------------------|---|--|--------------------------------------|-----------------|--------------------------------------|-------------------------------|----------------------------|---|--|---|
| Aydin (2020) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Yes | Yes |
| Buk (2020) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |
| Daglioglu (2018) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | No ^a | Yes | Yes |
| Daradka (2019) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |
| Dauser (2020) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | No ^b |
| Dzhumabekov (2019) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |
| Fresno (2010) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |
| Giusto (2017) | Yes | Yes | Yes | Unclear | Yes | Unclear | Yes | Yes | Yes | Yes |
| Göksu (2020) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |
| Gorur (2020) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Ye s |
| Ocak (2019) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |
| Özçay (2018) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |
| Pehlivanli (2016) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Yes | Yes |
| Sozutek (2016) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | No ^c | Yes | Yes |
| Yalı (2020) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | No ^d | Yes |
| Yamaguchi (2012) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Yes | Unclear |
| Yol (2008) | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Yes | Unclear |
| Zhou (2014) | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes | Yes |

Supplemental Table 2 SYRCLE's tool for assessing risk of bias

a: the authors excluded from the study unequal number of animals that died from different groups

b: Co-author(s) employed by a pharmaceutical company

c: The authors did not address the death of two animals in one of the groups

d: Tissue Hydroxyproline Level results are not reported although they are included as expected outcomes in the materials and method section.